Federal Register / Vol. 66, No. 107 / Monday, June 4, 2001 / Notices 29977

Type of respondent Number of respondents

Responses

per respondent

Total number

of responses

Burden per responses (minutes)

Total burden

hours

Applicants ............................................................................. 1,850 1 1,850 12 370

Lenders ................................................................................ 9 206 1,854 30 927

Total .............................................................................. 1,859 ........................ 3,704 ........................ 1,297

Send comments to Susan G. Queen,

Ph.D., HRSA Reports Clearance Officer,

Room 14–33, Parklawn Building, 5600

Fishers Lane, Rockville, MD 20857.

Written comments should be received

within 60 days of this notice.

Dated: May 25, 2001.

Jane M. Harrison,

Director, Division, of Policy Review and

Coordination.

[FR Doc. 01–13850 Filed 6–1–01; 8:45 am]

BILLING CODE 4160–15–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions;

Availability for Licensing

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below

are owned by agencies of the U.S.

Government and are available for

licensing in the U.S. in accordance with

35 U.S.C. 207 to achieve expeditious

commercialization of results of

federally-funded research and

development. Foreign patent

applications are filed on selected

inventions to extend market coverage

for companies and may also be available

for licensing.

ADDRESSES: Licensing information and

copies of the U.S. patent applications

listed below may be obtained by writing

to the indicated licensing contact at the

Office of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville,

Maryland 20852–3804; telephone: 301/

496–7057; fax: 301/402–0220. A signed

Confidential Disclosure Agreement will

be required to receive copies of the

patent applications.

PRAC & PRAC–Y: Small Nuclear

Proteins Found in Prostate and Colon

Cancer, and Uses Thereof

Ira Pastan et al. (NCI)

DHHS Reference No. E–053–01/0, filed

09 Apr 2001

Licensing Contact: Richard Rodriguez;

301/496–7056, ext. 287; e-mail:

rodrigur@od.nih.gov

Prostate cancer is the most commonly

diagnosed cancer and the second

leading cause of cancer death in males

in the United States. Currently, there are

no curative therapies available for this

cancer and therefore, novel approaches

are needed to treat this disease. The

present invention claims a small,

nuclear protein, PRAC (Prostate/Rectum

And Colon Protein) that could be used

to diagnose and/or treat prostate or

colon cancers. In conjunction with the

composition of matter claims, defined

methods of use might include: (1)

Immunogenic fragments to elicit T cell

responses against cells that express

PRAC; (2) gene therapy applications

through the use of appropriate

expression vectors containing the

nucleic acid sequences of PRAC; (3)

detection and potential staging of

cancers expressing PRAC. These

disclosed technologies could provide

new and exciting methodologies to treat

prostate and/or colon cancer.

Biologically Active Macrolides,

Compositions and Uses Thereof

Michael R. Boyd (NCI), Kirk R.

Gustafson (NCI), and Charles L.

Cantrell (USDA)

DHHS Reference No. E–203–00/0, filed

24 Jul 2000

Licensing Contact: Elaine White; 301/

496–7056, ext. 282; e-mail:

gesee@od.nih.gov

The current invention embodies the

identification of a novel class of potent

vacuolar-type (H+)-ATPase-inhibitory

compounds. Vacuolar-type (H+)-

ATPases are present in many tissues

and cells of the body and are involved

in the maintenance of various

physiological functions. The

modification of these functions, via

inhibition of vacuolar-type (H+)-

ATPases, may represent an effective

means of treating various disease states,

including Alzheimer’s disease,

glaucoma, and osteoporosis. In addition,

these inhibitors may also be of

particular value for use against cancer,

as vacuolar-type (H+)-ATPases have

been implicated in processes relating to

cellular proliferation, angiogenesis,

tumor cell invasiveness, metastasis, and

drug resistance.

Dated: May 24, 2001.

Jack Spiegel,

Director, Division of Technology,

Development and Transfer, Office of

Technology Transfer, National Institutes of

Health.

[FR Doc. 01–13886 Filed 6–1–01; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions;

Availability for Licensing

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below

are owned by agencies of the U.S.

Government and are available for

licensing in the U.S. in accordance with

35 U.S.C. 207 to achieve expeditious

commercialization of results of

federally-funded research and

development. Foreign patent

applications are filed on selected

inventions to extend market coverage

for companies and may also be available

for licensing.

ADDRESSES: Licensing information and

copies of the U.S. patent applications

listed below may be obtained by

contacting Peter A. Soukas, J.D., at the

Office of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville,

Maryland 20852–3804; telephone: 301/

496–7056 ext. 268; fax: 301/402–0220;

e-mail: soukasp@od.nih.gov. A signed

Confidential Disclosure Agreement will

be required to receive copies of the

patent applications.

Identification of New Small RNAs and

ORFs

Susan Gottesman (NCI), Gisela Storz

(NICHD), Karen Wassarman (NICHD),

Francis Repoila (NCI), Carsten

Rosenow (EM)

DHHS Reference No. E–072–01/0, filed

01 Feb 2001

The inventors have isolated a number

of previously unknown sRNAs found in

E. coli. Previous scientific publications

by the inventors and others regarding